Clinical Trial Detail

NCT ID NCT03267433
Title Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

mantle cell lymphoma

Therapies

Rituximab

Age Groups: adult senior

No variant requirements are available.